Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer-Reference-Cited by-同舟云学术

Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer

Published:2024-08 Issue: Volume:46 Page:102003
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Zucca Luis Eduardo Rosa^ORCID,Laus Ana Carolina,Sorroche Bruna Pereira^ORCID,Paro Eduarda,Sussuchi Luciane^ORCID,Marques Rui Ferreira^ORCID,Teixeira Gustavo Ramos^ORCID,Berardinelli Gustavo Noriz^ORCID,Arantes Lidia Maria Rebolho Batista^ORCID,Reis Rui Manuel^ORCID,Cárcano Flavio Mavignier^ORCID

Publisher

Elsevier BV

Reference53 articles.

1. Epidemiology of Bladder Cancer;Saginala;Medical sciences,2020

2. Epidemiology of bladder cancer in 2023: a systematic review of risk factors;Jubber;Eur. Urol.,2023

3. Bladder cancer — cancer stat facts. Accessed in March 4th, 2024. https://seer.cancer.gov/statfacts/html/urinb.html.

4. European association of urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ);Babjuk;Eur. Urol.,2022

5. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus calmette-guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance;Oddens;Eur. Urol.,2013

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehending the pharmacological mechanism of marine phenolic acids in bladder cancer therapy against matrix metalloproteinase 9 protein by integrated network pharmacology and in-silico approaches;Computational Biology and Chemistry;2024-10